Procter & Gamble Health Ltd
NSE:PGHL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (36.5), the stock would be worth ₹6 446.44 (24% upside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 29.5 | ₹5 216.9 |
0%
|
| 3-Year Average | 36.5 | ₹6 446.44 |
+24%
|
| 5-Year Average | 37.4 | ₹6 613.59 |
+27%
|
| Industry Average | 30.4 | ₹5 367.24 |
+3%
|
| Country Average | 28.7 | ₹5 075.22 |
-3%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
₹85.1B
|
/ |
Jan 2026
₹2.9B
|
= |
|
|
₹85.1B
|
/ |
Mar 2026
₹3.2B
|
= |
|
|
₹85.1B
|
/ |
Mar 2027
₹3.7B
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| IN |
|
Procter & Gamble Health Ltd
NSE:PGHL
|
86.6B INR | 29.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 27.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 17.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 18.9 |
| Median | 28.7 |
| 70th Percentile | 44.4 |
| Max | 877 228.1 |
Other Multiples
Procter & Gamble Health Ltd
Glance View
In the vast landscape of healthcare, Procter & Gamble Health Ltd. carves its niche by blending science with daily life, transforming mundane routines into healthier lifestyles. Originally known for its parent company’s deep roots in consumer goods, P&G Health Ltd. has transitioned seamlessly into the pharmaceutical domain, focusing on over-the-counter (OTC) health products and supplements. Its journey is one of leveraging brand trust and an extensive distribution network to ensure that essential health solutions are accessible to consumers around the globe. P&G Health's emphasis on consumer awareness and education propels its growth, as it capitalizes on the modern consumer’s desire for self-care and proactive health management. At the heart of its business model lies a portfolio of products that spans various health categories, encapsulating vitamins, minerals, and supplements that address widespread health needs such as digestive wellness and immunity. The company thrives on innovation and strategic collaboration, utilizing a mix of in-house research alongside partnerships to remain at the forefront of consumer health trends. Revenue streams are buoyed by the strength of its established global market presence and regional expertise, ensuring adaptability across diverse economic landscapes. By catering to both established and emerging markets, Procter & Gamble Health Ltd. sustains its growth momentum, continuously refining its product offerings to meet the dynamic demands of health-conscious consumers.